ERBB2 and neoplasm: The stabilization or increase the T:B over time found in our data and the above reports is consistent with tumor retention of HER2 EBD-111In-trastuzumab or −89Zr-N-SucDf-trastuzumab complexes either intracellularly or on the tumor surface were independent of blood clearance.